T-cell vaccination against anti-CD4 autoimmunity in HIV-1 subtypes B and C-infected patients - An extended open trial

Rivka Abulafia-Lapid; Shlomo Mayan; Zvi Bentwich; Yael Keren-Zur; Yulia Avbramovitz; Irun R. Cohen; Henri Atlan

doi:10.1016/j.vaccine.2005.01.054

T-cell vaccination against anti-CD4 autoimmunity in HIV-1 subtypes B and C-infected patients - An extended open trial

Rivka Abulafia-Lapid, Shlomo Mayan, Zvi Bentwich, Yael Keren-Zur, Yulia Avbramovitz, Irun R. Cohen, Henri Atlan

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

This study is an extended clinical trial of the one initiated and reported in the Journal of Clinical Virology 2004;31S:S48-54. Thirteen HIV-1 patients (eight subtype B and five subtype C) that manifested T-cell autoimmunity to recombinant human CD4 (rCD4) were treated with T-cell vaccine composed of glutaraldehyde-treated autologous anti-CD4 reactive T-cells and compared to historical seven non-vaccinated HIV-1-infected subjects. This study proved to be feasible and safe. Follow-up study revealed that 7/8 subtype B and 2/4 subtype C patients (one has just received the first TCV injection) responded with a persistent increase in their blood CD4 T-cell levels and four subtype B patients manifested decreased anti-CD4 autoimmunity. Despite highly active antiretroviral therapy (HAART), the persistence of CD4 T-cell lymphopenia may be associated with anti-CD4 autoimmunity. T-cell vaccination (TCV) may decrease such autoimmunity and elevate CD4 T-cell numbers.

Original language	English
Pages (from-to)	2149-2153
Number of pages	5
Journal	Vaccine
Volume	23
Issue number	17-18
DOIs	https://doi.org/10.1016/j.vaccine.2005.01.054
State	Published - 18 Mar 2005
Externally published	Yes

Keywords

Autoimmunity
HIV-1 subtypes B and C
T-cell vaccination

ASJC Scopus subject areas

Molecular Medicine
Immunology and Microbiology (all)
Veterinary (all)
Public Health, Environmental and Occupational Health
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.vaccine.2005.01.054

Cite this

@article{7ea036aafa464ba68e3dc161eea8b3a6,

title = "T-cell vaccination against anti-CD4 autoimmunity in HIV-1 subtypes B and C-infected patients - An extended open trial",

abstract = "This study is an extended clinical trial of the one initiated and reported in the Journal of Clinical Virology 2004;31S:S48-54. Thirteen HIV-1 patients (eight subtype B and five subtype C) that manifested T-cell autoimmunity to recombinant human CD4 (rCD4) were treated with T-cell vaccine composed of glutaraldehyde-treated autologous anti-CD4 reactive T-cells and compared to historical seven non-vaccinated HIV-1-infected subjects. This study proved to be feasible and safe. Follow-up study revealed that 7/8 subtype B and 2/4 subtype C patients (one has just received the first TCV injection) responded with a persistent increase in their blood CD4 T-cell levels and four subtype B patients manifested decreased anti-CD4 autoimmunity. Despite highly active antiretroviral therapy (HAART), the persistence of CD4 T-cell lymphopenia may be associated with anti-CD4 autoimmunity. T-cell vaccination (TCV) may decrease such autoimmunity and elevate CD4 T-cell numbers.",

keywords = "Autoimmunity, HIV-1 subtypes B and C, T-cell vaccination",

author = "Rivka Abulafia-Lapid and Shlomo Mayan and Zvi Bentwich and Yael Keren-Zur and Yulia Avbramovitz and Cohen, {Irun R.} and Henri Atlan",

note = "Funding Information: We would like to thank Michelle Haouzi Bashan, R.N., for clinical assistance in this project. The work was supported by grants from the Ishaia Horowitz Foundation, and the Institute for Advanced Therapy, New York, USA. ",

year = "2005",

month = mar,

day = "18",

doi = "10.1016/j.vaccine.2005.01.054",

language = "English",

volume = "23",

pages = "2149--2153",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "17-18",

}

TY - JOUR

T1 - T-cell vaccination against anti-CD4 autoimmunity in HIV-1 subtypes B and C-infected patients - An extended open trial

AU - Abulafia-Lapid, Rivka

AU - Mayan, Shlomo

AU - Bentwich, Zvi

AU - Keren-Zur, Yael

AU - Avbramovitz, Yulia

AU - Cohen, Irun R.

AU - Atlan, Henri

N1 - Funding Information: We would like to thank Michelle Haouzi Bashan, R.N., for clinical assistance in this project. The work was supported by grants from the Ishaia Horowitz Foundation, and the Institute for Advanced Therapy, New York, USA.

PY - 2005/3/18

Y1 - 2005/3/18

N2 - This study is an extended clinical trial of the one initiated and reported in the Journal of Clinical Virology 2004;31S:S48-54. Thirteen HIV-1 patients (eight subtype B and five subtype C) that manifested T-cell autoimmunity to recombinant human CD4 (rCD4) were treated with T-cell vaccine composed of glutaraldehyde-treated autologous anti-CD4 reactive T-cells and compared to historical seven non-vaccinated HIV-1-infected subjects. This study proved to be feasible and safe. Follow-up study revealed that 7/8 subtype B and 2/4 subtype C patients (one has just received the first TCV injection) responded with a persistent increase in their blood CD4 T-cell levels and four subtype B patients manifested decreased anti-CD4 autoimmunity. Despite highly active antiretroviral therapy (HAART), the persistence of CD4 T-cell lymphopenia may be associated with anti-CD4 autoimmunity. T-cell vaccination (TCV) may decrease such autoimmunity and elevate CD4 T-cell numbers.

AB - This study is an extended clinical trial of the one initiated and reported in the Journal of Clinical Virology 2004;31S:S48-54. Thirteen HIV-1 patients (eight subtype B and five subtype C) that manifested T-cell autoimmunity to recombinant human CD4 (rCD4) were treated with T-cell vaccine composed of glutaraldehyde-treated autologous anti-CD4 reactive T-cells and compared to historical seven non-vaccinated HIV-1-infected subjects. This study proved to be feasible and safe. Follow-up study revealed that 7/8 subtype B and 2/4 subtype C patients (one has just received the first TCV injection) responded with a persistent increase in their blood CD4 T-cell levels and four subtype B patients manifested decreased anti-CD4 autoimmunity. Despite highly active antiretroviral therapy (HAART), the persistence of CD4 T-cell lymphopenia may be associated with anti-CD4 autoimmunity. T-cell vaccination (TCV) may decrease such autoimmunity and elevate CD4 T-cell numbers.

KW - Autoimmunity

KW - HIV-1 subtypes B and C

KW - T-cell vaccination

UR - http://www.scopus.com/inward/record.url?scp=14844296988&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2005.01.054

DO - 10.1016/j.vaccine.2005.01.054

M3 - Article

C2 - 15755585

AN - SCOPUS:14844296988

SN - 0264-410X

VL - 23

SP - 2149

EP - 2153

JO - Vaccine

JF - Vaccine

IS - 17-18

ER -

T-cell vaccination against anti-CD4 autoimmunity in HIV-1 subtypes B and C-infected patients - An extended open trial

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this